

Ventilación No Invasiva en Pediatría

KLGO. JOSÉ LANDEROS



1

Evidencias

Falla Respiratoria Aguda Hipoxémica

Akingbola OA *Critical Care Medicine* 1994; 22:A144

Estudio retrospectivo BiPAP-S/ Máscara nasal 8m-20m

Intubados 0/9, mejoría del intercambio gaseoso a la hora

Fortenberry JD *Chest* 1995; 108:1059-1064

Estudio retrospectivo BiPAP S/Máscara nasal 4m-17a

Intubados 3/28, mejoría del intercambio gaseoso a la hora

Padman R *Critical Care Medicine*; 1998; 26:169-173

Estudio prospectivo BiPAP-ST/Máscara nasal 6m-20a

Intubados 3/34, mejoría del intercambio gaseoso, FR, FC y disnea a las 72 horas

2

Falla respiratoria hipercárbica

Padman R Pediatric Pulmonology 1994; 17:119-123

Estudio retrospectivo BiPAP-S Máscara nasal 4a-21a

Intubados 1/8, mejoría de FC,FR y HCO₃ a las 72 h

Padman R Respiratory Care 1994; 39:736-739

Estudio retrospectivo BiPAP-S Máscara nasal 7a-30a

Intubados 0/9, mejoría de FC,FR y HCO₃ a las 72 h

Niranjan V Critical Care Medicine 1998;26: 2061-2065

Estudio de casos control BiPAP-ST Máscara nasal 13a-21a

Intubados 0/10

Hertzog JH Paediatric Anaesthesia 1996;6:219-224

Estudio retrospectivo BiPAP-S Máscara nasal 4a-20a

Intubados 5/11, mejoría de intercambio gaseoso y t de estadía en UTI

3

The screenshot shows the PubMed.gov homepage. At the top, there is a search bar with "PubMed" selected from a dropdown menu. To the right of the search bar are links for "Limits", "Advanced search", and "Help". Below the search bar is a large input field for entering search terms, with a "Search" button to its right. Underneath this, there are two rows of text. The first row contains "Display Settings: Abstract" and "Send to: ()". The second row contains the citation information for a medical article.

Am J Phys Med Rehabil. 1989 Dec;68(6):264-71.

Management alternatives for post-polio respiratory insufficiency. Assisted ventilation by nasal or oral-nasal interface.

Bach JR, Alba AS, Shin D.

Department of Physical Medicine and Rehabilitation, University Hospital, New Jersey Medical School, Newark.

4

Noninvasive positive-pressure ventilation in children with lower airway obstruction*

Peter J. Thill, MD; John K. McGuire, MD; Harris P. Baden, MD; Thomas P. Green, MD;
Paul A. Checchia, MD, FAAP

Pediatr Crit Care Med 2004 Vol. 5, No. 4

Table 1. Clinical Asthma Score


Severity	Accessory Muscle Score	Wheeze Score	Dyspnea Score
0	No retractions	No wheeze	Absent dyspnea
1	Intercostal retractions	End-expiratory wheeze	Normal activity and speech, minimal dyspnea
2	Intercostal and suprasternal retractions	Pan-expiratory \pm inspiratory wheeze	Decreased activity, 5–8 word sentences, moderate dyspnea
3	Nasal flaring	Wheeze audible without stethoscope	Concentrates on breathing, <5-word sentences, severe dyspnea

Reproduced with permission from Schuh et al (14).

Methods: Children were randomized to receive either 2 hrs of non-invasive ventilation followed by crossover to 2 hrs of standard therapy or 2 hrs of standard therapy followed by 2 hrs of noninvasive ventilation.


5

Score de Asma



6

3



7

	Control group	BPAP group	P value
Resp rate(breath/min)			
Baseline	49.6 ± 12.2	49.8 ± 14.4	NS
1	45.8 ± 11.8	$35.5 \pm 10.9^{**}$	0.004
6	48.05 ± 11.7	37 ± 12.4	NS
12	41 ± 12.02	33.3 ± 9.6	NS
24	44.4 ± 13.6	31.3 ± 8.6	NS
48	33.6 ± 11.9	30.7 ± 8.8	NS

A prospective, randomized, controlled trial of noninvasive ventilation in pediatric acute respiratory failure*

Pediatr Crit Care Med 2008 Vol. 9, No. 5

8

	Control group	BPAP group	P value
PaFi			
Baseline	204 ± 87.1	172.6 ± 75.8	NS
1	222.8 ± 104.3	240.5 ± 97.3***	NS
6	210.1 ± 61.1	217.9 ± 90.3	NS
12	224.9 ± 109.9	232.4 ± 81.6	NS
24	212 ± 82.5	269.6.± 99.8	NS
48	221.6 ± 92.4	255..6 ± 108.2	NS

A prospective, randomized, controlled trial of noninvasive ventilation in pediatric acute respiratory failure*

Pediatr Crit Care Med 2008 Vol. 9, No. 5


9

Complicaciones

	Control group (n=25)	BPAP group (n=25)	P value
Intubation (Nº)	15 (60%)	7 (28%)	0.045
Ventilator associated pneumonia	2/15	2/7	
Postextubation Laryngitis	1/15	1/7	
Period of MV (mean days)	3.12	2.64	
ICU stay (mean days)	5.48	6.68	NS
Hospital stay (mean days)	10.6	10.4	


10

Paciente que responde



11

Paciente que no responde



12



13

Efectos fisiológicos

- Reducción del trabajo ventilatorio inspiratorio con mejoría del patrón ventilatorio y del intercambio gaseoso.
Essouri et al, Intensive Care Med 2008
Stucky et al, Intensive Care Med 2009
- Incremento de la oxigenación y de la remoción del CO₂: Reclutamiento alveolar
- Prevención de las apneas en RNPT, por estabilización de la parrilla costal y de la vía aérea superior

14

OPEN

Outcomes for Children Receiving Noninvasive Ventilation as the First-Line Mode of Mechanical Ventilation at Intensive Care Admission: A Propensity Score-Matched Cohort Study

Jenny V. Morris, MSc¹; Padmanabhan Ramnarayan, FFICM²; Roger C. Parslow, PhD¹; Sarah J. Fleming, PhD¹

Cohorte Prospectiva 2007-2014 / 31 UCIP
 Pacientes ingresados a UCIP que recibieron VM desde el primer día
 151.128 ingresos / 15.144 elegibles
 4.804 recibieron VNI inicial
 10.221 recibieron VM Invasiva inicial

Crit Care Med 2017 Jun; 45(6):1045-1053

15

TABLE 2. Crude Outcomes for Patients Included in the Whole Cohort (*n* = 15,025) and Propensity Score-Matched Cohort (*n* = 6,002)

Outcome	Whole Cohort (<i>n</i> = 15,025)			Propensity Score Matching Cohort (<i>n</i> = 6,002)		
	Invasive Ven-tilation (<i>n</i> = 10,221)	NIV (<i>n</i> = 4,804)	<i>p</i>	Invasive Ven-tilation (<i>n</i> = 3,001)	NIV (<i>n</i> = 3,001)	<i>p</i>
PICU mortality (%)	9.6	4.4	< 0.001	8.5	5.9	< 0.001
Length of ventilation (d), median (IQR)	4 (2–7)	4 (2–7)	< 0.001	5 (3–9)	4 (2–7)	< 0.001
Length of stay (d), median (IQR)	5 (2–9)	5 (3–8)	< 0.001	6 (4–11)	5 (3–9)	< 0.001
VFD-28—all patients, median (IQR)	8 (0–24)	12 (0–22)	0.016	0 (0–16)	8 (0–22)	< 0.001
VFD-28—survivors only, median (IQR)	12 (0–24)	12 (0–22)	0.269	0 (0–16)	12 (0–22)	< 0.001
NIV failure rate, <i>n</i> (%)	NA	1,237 (25.7)	NA	NA	948 (33.3)	NA

IQR = interquartile range, NA = not applicable, NIV = noninvasive ventilation, VFD-28 = ventilation-free days at day 28.

A Wilcoxon rank-sum test was used to compare all continuous variables presented as mean (interquartile range), a two sample *t* test was used to compare continuous variables presented as mean (sd), and chi-square test of independence compared all categorical variables presented as *n* (%).

16

Característica	COHORTE (n=15.025)			Análisis de Propensión		
	VMI (n=10.221)	VMNI (n=4.804)	p	VMI (n=3.001)	VM(n=3.001)	p
Arterial or capillary blood gas taken, ^b n (%)						
Yes	7,588 (74.2)	2,925 (60.9)	< 0.001	2,093 (69.7)	2,133 (71.1)	0.258
Lactate, ^b median (IQR)	1.9 (1.1–3.7)	1.6 (1.1–2.6)	< 0.001	1.8 (1.0–3.5)	1.6 (1.1–2.6)	0.014
Not recorded, n (%)	6,798 (66.5)	3,347 (69.7)		64.9	65.4	
Pao ₂ /FiO ₂ ratio, ^b median (IQR)	190.6 (102.6–354.6)	129.4 (85.7–200)	< 0.001	150 (86–258)	129 (84–202)	< 0.001
Not recorded, n (%)	5,923 (57.9)	3,998 (83.2)		64.7	78.2	
Base excess, ^b median (IQR)	-3.1 (-7.0 to 0.3)	1.0 (-2.0 to 4.8)	< 0.001	-1.4 (-5.3 to 2.1)	0.9 (-2.3 to 4.9)	< 0.001
Not recorded, n (%)	3,201 (31.3)	2,186 (45.5)		1,035 (34.5)	1,080 (36.0)	
Age-standardized systolic blood pressure ^b z score, mean (sd)	-0.03 (1.18)	0.13 (0.98)	< 0.001	0.061 (1.02)	0.089 (1.02)	0.288

17

Teague [33]. ARF with ventilation-perfusion impairment, hypoxemia and parenchymal condensations on X-ray was considered as type 1. ARF with hypoventilation, hypercapnia without hypoxemia, and parenchymal condensations absence on X-ray (excluding atelectasis) was considered as type 2. Bronchiolitis was the only ARF cause classified in either type 1 or 2 group.




Fig. 2 Evolution of respiratory rate at the hours studied in type 1 and 2 acute respiratory failure groups. ARF acute respiratory failure

hypercapnic acute respiratory failure (ARF) due to conventional medical therapy [13]. NIV diminishes the

18

Table 3 Parameters with significant differences between success and failure groups expressed in mean \pm standard deviation (except for age and weight, expressed in median and range)

	Success group (N = 98)	Failure group (N = 18)	P value
Age (months)	11.6 (0.6–169.7) (N = 98)	6.1 (0.8–115.9) (N = 18)	0.028
Weight (kg)	9.6 (2.8–58.0) (N = 98)	6.3 (2.8–39.0) (N = 18)	0.016
PRISM score	7.4 \pm 4.4 (N = 98)	11.7 \pm 7.6 (N = 18)	0.026
HR at 24 h (beats/min)	129.7 \pm 22.2 (N = 83)	149.6 \pm 20.9 (N = 8)	0.033
RR at 24 h (breaths/min)	35.7 \pm 8.3 (N = 83)	48.9 \pm 11.6 (N = 8)	0.001
EPAP at 24 h (cmH ₂ O)	6.4 \pm 1.3 (N = 83)	7.9 \pm 1.0 (N = 8)	0.001
EPAP at 48 h (cmH ₂ O)	6.5 \pm 1.5 (N = 52)	9 \pm 2.6 (N = 4)	0.040
RR decrease in the first hour (breaths/min)	12.2 \pm 12.9 (N = 98)	4.9 \pm 11.9 (N = 18)	0.032
RR decrease at 24 h (breaths/min)	17.8 \pm 16.4 (N = 83)	3.1 \pm 18.2 (N = 8)	0.015
FiO ₂ at 1 h (%)	43.3 \pm 18.9 (N = 98)	50.5 \pm 19.0 (N = 18)	0.040
FiO ₂ at 6 h (%)	37.9 \pm 14.6 (N = 98)	46.5 \pm 14.7 (N = 13)	0.025
FiO ₂ at 24 h (%)	32.8 \pm 9.4 (N = 83)	45.0 \pm 14.9 (N = 8)	0.015
FiO ₂ at 48 h (%)	31.6 \pm 8.9 (N = 52)	50.0 \pm 14.1 (N = 4)	0.006
Venous PCO ₂ at 6 h (mmHg)	46.5 \pm 9.9 (N = 19)	65.9 \pm 10.7 (N = 3)	0.021
Venous PCO ₂ at 24 h (mmHg)	46.5 \pm 7.6 (N = 19)	78.1 \pm 36.8 (N = 3)	0.030

Number of episodes analyzed in each item is specified beside
HR heart rate, *RR* respiratory rate, *EPAP* expiratory pressure, *PRISM* paediatric risk of mortality


19

Factores de Riesgo de Fracaso de NIV


	Success group (N = 98)	Failure group (N = 18)	P value
Variable			
Age (months)	11.6 (0.6–169.7)	6.1 (0.8–115.9)	0.028
Males	62.2%	77.8%	0.205
Weight (kg)	9.6 (2.8–58.0)	6.3 (2.8–39.0)	0.016
PRISM score	7.4 \pm 4.4	11.7 \pm 7.6	0.026
HR (beats/min)	162.4 \pm 30.2	165.1 \pm 22.4	0.972
RR (breaths/min)	53.5 \pm 18.2	47.5 \pm 14.5	0.231
FiO ₂ (%)	43.6 \pm 23.5	40.8 \pm 24.9	0.293
Venous PCO ₂ (mmHg)	48.6 \pm 14.9	57.8 \pm 14.3	0.062

- Falla aguda Tipo 1 (condensación)
- PRISM > 10
- Baja disminución de la FR la primera hora

20



21




22

Juan Mayordomo-Colunga
 Martí Pons
 Yolanda López
 M. José Solana
 Corsino Rey
 Pablo Martínez-Camblor
 Antonio Rodríguez-Núñez
 Jesús López-Herce
 Alberto Medina
 Clara Abadesso
 M. Angeles García-Teresa
 Mirella Gáboli
 Milagros García-López
 María González-Sánchez
 Paula Madurga-Revilla
 Amelia González-Calvar
 Eider Oñate

Predicting non-invasive ventilation failure in children from the $\text{SpO}_2/\text{FiO}_2$ (SF) ratio



23



24

Table 2 Demographic and baseline characteristics of the successful and failed episodes

Patients' characteristics	Success group (N = 317)	Failure group (N = 73)	P value
Age (months)	6.6 (1.6–30)	5.8 (1.4–14.7)	0.015
Males (%)	89.1	86.2	0.631
Weight (kg)	7 (4.4–13)	6 (3.5–10)	0.036
Deaths	6 (1.9 %)	9 (12.3 %)	<0.001
PRISM III-24 score	3 (0–4)	5.5 (1–9)	<0.001
HR (beats/min)	101 (140–180)	153 (145–172)	0.471
RR (breaths/min)	49 (37–62)	43 (30.2–55)	0.071
FiO ₂ (%)	40 (28–75)	50 (30–72)	0.304
SpO ₂	96 (92–99)	97 (97–99)	0.005
Venous PCO ₂ (mmHg)	53.9 (44.4–64.2)	59.5 (49.2–74)	0.040
SF ratio	270 (153.7–372.8)	208.5 (162.3–329.1)	0.170
Venous pH	7.31 (7.25–7.37)	7.3 (7.25–7.34)	0.926
Venous lactate	1.7 (1.2–2.4)	1.4 (1.1–3.1)	0.756
NIV duration (hours)	60 (33–91)	13 (4–32.5)	<0.001

Data are expressed as median (interquartile range), or percentage. P values refer to the differences between NIV success and failure groups. PRISM III-24 was calculated within the first day of PICU admission

25

Table 3 Predictive models of NIV outcomes. No predictive model could be calculated for episodes failing after 24 h upon NIV initiation

	AUC (CI 95 %)	Cutoff value (Sn – Sp)	PPV (CI 95 %)	NPV (CI 95 %)
Whole sample				
–0.059 × SF ratio at 1 h (10 units) – 0.030 × age (months) + 0.208 × PRISM III-24	0.755 (0.661–0.849)	–1.310 (86.2–57.8)	26.9 % (17.3–36.4)	95.9 % (89.8–98.9)
Episodes failing before 6 h				
SF ratio at 1 h	0.748 (0.588–0.908)	193 (77.8–70)	10.9 % (2.5–19.4)	98.5 % (94.6–99.8)
Episodes failing between 6 and 24 h				
0.202 × PRISM III-24 – 0.074 × RR decrease at 6 h – 0.008 × SF ratio at 6 h (10 units)	0.895 (0.800–0.990)	–0.8 (87.5–83)	31.8 % (16.9–46.7)	98.5 % (94.9–99.8)

AUC area under the curve, CI confidence interval, Sn sensitivity (in %), Sp specificity (in %), PPV positive predictive value, NPV negative predictive value, PRISM pediatric risk of mortality

26

Pacientes con mayor riesgo de fracaso de la VNI inicial

- **Hipoxemia (FRA Tipo I)**
- Cociente SF < 200 1-2-6 horas
- SDRA
- **Edad**
- Lactantes < 6 meses
- **NO MEJORA TRABAJO VENTILATORIO**
- No descenso de FR y FC a 2 horas
- Mayor IPAP a 2 horas; MAP > 11,5
- **pH < 7,25**
- **PRISM o PELOD elevado**


Martí Pons

27




FRA HIPOXÉMICA:
SF < 270

Aplicar CPAP 5 cmH₂O x 5 min
Posteriormente BiPAP



28




29

Factores de riesgo de fracaso de VNI

- Menores de 6 meses
- FRA Tipo 1 (Hipoxemia)
- Baja disminución de la FR y FC a la hora 1 (< 10 puntos para ambas)
- Baja disminución de la PaCO₂ a la hora 2 (<12 mmHg)
- Baja Sa/Fi a la hora 1-2 (< 200)
- Factor de riesgo cultural



30



31

Aplíquela ANTES que el paciente esté agotado

SIRVE PARA TODAS
LAS TERAPIAS...

32